Furthermore, it has been suggested that IL-6, IL-2, and probably IL-1β, can be considered as state markers in SSD, which decrease after the initiation of AP therapy, whereas TNF-α and IFN-γ have been considered as trait markers [54,55]. The gene discussed is IL2; the disease is alkaline phosphatase measurement.